# Immune measurements and product evidence

Source: https://onco.cc/terms/immune-product-evidence/  
OnCo record `immune-product-evidence` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Each immune test or product-quality check answers a particular question. Connecting those questions helps explain how a proposed treatment moves from molecular measurements to evidence in people.

## Summary

This reading map links immune-assay readouts, antigen evidence, specimen preparation, RNA design, recognition modules and product quality. It is a set of evidence questions, not a required experimental sequence. Receptor binding, cytokine release, cell killing, lot potency and clinical benefit are different observations. A useful explanation names the sample, assay, model and comparison that support the claim, including the steps that remain untested.

## Fields

- Kind: Term
- Last checked: 2026-11-08

## Sources

- Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides.: https://doi.org/10.1186/1471-2172-9-9
- Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry.: https://doi.org/10.1038/ncomms13404
- FDA: Potency Assurance for Cellular and Gene Therapy Products, final guidance (November 2026): https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-potency-assurance-cellular-and-gene-therapy-products

## Connected records

- terms: [Binder affinity, epitope and developability](https://onco.cc/terms/binder-affinity-epitope-developability/), [Binders as targeting modules](https://onco.cc/terms/binder-targeting-module/), [Cell segmentation in tissue measurements](https://onco.cc/terms/cell-segmentation/), [Certificate of analysis](https://onco.cc/terms/certificate-of-analysis/), [Chemistry, manufacturing and controls](https://onco.cc/terms/chemistry-manufacturing-controls/), [Codon optimization](https://onco.cc/terms/codon-optimization/), [Comparability after manufacturing changes](https://onco.cc/terms/manufacturing-process-comparability/), [Delivery targets and therapeutic targets](https://onco.cc/terms/delivery-target-versus-therapeutic-target/), [Double-stranded RNA impurities](https://onco.cc/terms/dsrna-impurities/), [ELISpot secretion assays](https://onco.cc/terms/elispot/), [Epitope spreading](https://onco.cc/terms/epitope-spreading/), [Finite tissue and specimen allocation](https://onco.cc/terms/finite-tissue-budget/), [Format-dependent binder function](https://onco.cc/terms/binder-format-constraints/), [Immune-cell cytotoxicity assays](https://onco.cc/terms/immune-cytotoxicity-assays/), [Immunodominance](https://onco.cc/terms/immunodominance/), [Immunogenicity and clinical efficacy](https://onco.cc/terms/immunogenicity-versus-efficacy/), [Immunopeptidome](https://onco.cc/terms/immunopeptidome/), [Immunopeptidomics](https://onco.cc/terms/immunopeptidomics/), [In vitro transcription for RNA products](https://onco.cc/terms/in-vitro-transcription/), [Intracellular cytokine staining](https://onco.cc/terms/intracellular-cytokine-staining/), [Messenger RNA construct anatomy](https://onco.cc/terms/mrna-construct-anatomy/), [Modified nucleosides in messenger RNA](https://onco.cc/terms/modified-rna-nucleosides/), [Multi-epitope constructs and antigen processing](https://onco.cc/terms/multi-epitope-constructs/), [Neoantigen](https://onco.cc/terms/neoantigen/), [Peptide binding, presentation and immune recognition](https://onco.cc/terms/binding-presentation-recognition/), [Peptide-HLA binding and ligand prediction](https://onco.cc/terms/peptide-hla-binding-prediction/), [Peptide-HLA multimer staining](https://onco.cc/terms/peptide-hla-multimer-staining/), [Peripheral blood mononuclear cell specimens](https://onco.cc/terms/pbmc-specimens/), [RNA integrity and assay suitability](https://onco.cc/terms/rna-integrity/), [Self-similarity and immune-recognition specificity](https://onco.cc/terms/self-similarity-immune-recognition/), [Single-chain and single-domain antibody fragments](https://onco.cc/terms/scfv-vhh-formats/), [Specimen provenance and derivative tracking](https://onco.cc/terms/specimen-provenance/), [T-cell receptor repertoire diversity and clonality](https://onco.cc/terms/tcr-repertoire-clonality/), [T-cell receptor repertoire sequencing](https://onco.cc/terms/tcr-repertoire-sequencing/), [Targeted proteomics and quantification limits](https://onco.cc/terms/targeted-proteomics-quantification/), [Tissue preparation and assay suitability](https://onco.cc/terms/tissue-preparation-assay-fit/)

---
JSON: https://onco.cc/api/v1/entities/immune-product-evidence.json